Meet our customers

“Since our founding, science has remained our central guiding principle. Benchling fits perfectly into this philosophy, providing us a flexible informatics platform that enables our scientists to focus on high-impact research and deliver life-transforming medicines.”
Nicholas Papadopoulos SVP R&D Operations, Regeneron

More than 170,000 scientists worldwide across pharma, biotech, and academia

  • Pfizer

    One of the world's largest pharmaceutical companies developing cutting-edge drugs in immunology, oncology, cardiology, and more.
  • Regeneron

    A leading biotechnology company using the power of science to bring new medicines to patients in need.
  • Eisai

    Eisai is a human health care (hhc) company seeking innovative solutions in disease prevention, treatment and care for the health and well-being of people worldwide.
  • Zoetis

    Zoetis is a global animal health company dedicated to supporting customers and their businesses in ever better ways, delivering medicines, vaccines, and diagnostic products.
  • Ginkgo

    Ginkgo Bioworks is designing custom organisms for customers across multiple markets, learning from nature to replace technology with biology.
  • Sorrento

    Sorrento Therapeutics is a clinical stage, antibody-centric biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possible curable diseases.
  • CytomX

    CytomX is a clinical-stage biopharmaceutical company – intent on revolutionizing the way we treat cancer.
  • Bolt Threads

    Bolt Threads is bioengineering the next generation of fabrics and garments with their Microsilk and Mylo technologies.
  • Editas

    A leading genome editing company dedicated to treating patients with genetically defined diseases.
  • Rubius

    Rubius Therapeutics is realizing the power of red by creating red blood cells and transforming them into cellular medicines.
    Case Study
  • Incyte

    Investigating the immune-suppressive tumor microenvironment through both small and large molecule approaches that target diverse mechanisms.
  • Xencor

    Expanding the therapeutic boundaries of monoclonal antibody drugs with its XmAb antibody engineering platform.
  • Agenus

    Using the power of the immune system to develop a broad range of innovative therapeutic antibody and vaccine candidates against cancer.
    Case Study
  • New England Biolabs

    Recombinant and native enzyme reagents for life science research. Provides solutions supporting genome editing, synthetic biology and next-generation sequencing.
  • uniQure

    Delivering on the promise of gene therapy, single treatments with potentially curative results.
  • Lung Biotechnology

    Lung Biotechnology's mission is to simplify and democratize the treatment of lung disease, using biotechnology to design therapies for PAH and other fatal lung diseases.
  • Mammoth Biosciences

    Mammoth Biosciences provides a CRISPR-based platform for disease detection across healthcare, agriculture, and other industries
  • Synlogic

    working at the intersection of biology and engineering, pioneering the application of synthetic biology to design living therapeutics programmed to treat disease in new ways
    Case Study
  • Genus

    Investigating the application of novel gene editing technologies towards bovine genetics.
  • Voyager Therapeutics

    Developing life-changing gene therapies with a focus on severe neurological diseases that lack safe and effective treatment options.
  • Zymergen

    Unlocking the power of biology to make strain optimization as reliable and predictable as other engineering processes.
    Case Study
  • Surrozen Therapeutics

    Surrozen is discovering and developing novel regenerative medicines with a focus on unlocking the powerful self-renewal properties of the body through specific control of the Wnt signaling pathway.
  • Caribou Biosciences

    Advancing new applications for CRISPR-Cas gene editing to help bring the promise this technology holds for patients and consumers to reality.
  • Arcturus Therapeutics

    An industry leader in the application of RNA technologies for the treatment of disease and improved quality of life.
    Case Study
  • IGM Biosciences

    IGM is pioneering the development of the IgM class of antibodies as therapeutic treatments for human disease.
  • Translate Bio

    Translate Bio is an mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction.
  • Diassess

    Diassess's product detects the genetic information of disease pathogens using nucleic acid amplification to provide a highly accurate diagnosis.
  • Inhibrx

    Enabling fit-for-function biotherapeutics that optimally interface with the biology of each target antigen, focus immune activation, and mediate enhanced signaling.
  • Jnana Therapeutics

    Jnana is pushing the frontiers of knowledge and technology to decipher the language of cellular metabolite communication and unlock SLC transporters as a therapeutic target class.
  • Tenaya Therapeutics

    Tenaya is addressing heart failure through multipronged efforts that target the fundamental cellular pathologies present in diseased cardiac muscle.
  • Asimov

    Asimov strives to enable biotechnologies with global benefit by combining synthetic biology and computer science.
  • Dragonfly Therapeutics

    Developing novel first-in-class therapeutics targeted at Natural Killer cells and other cells of the innate immune system.
  • Adimab

    A premier human antibody discovery and optimization platform defined by speed, diversity, and quality.
  • Horizon

    A leading gene editing company that designs and engineers genetically modified cells for clinical applications.
  • Synpromics

    Improving human health by enabling safer, more effective cell and gene medicines through proprietary genomics, bioinformatics and intelligent data driven design.
  • Ligand Pharmaceuticals

    Ligand has one of the largest and most diverse portfolios in the pharmaceutical industry. Currently approved portfolio drugs include those that treat cancer, osteoporosis, and fungal infections.
  • ABL Bio

    ABL Bio is one of the world's leading biotech research companies focusing on the development of therapeutic drugs for immuno-oncology & neurodegenerative diseases.
  • Obsidian Therapeutics

    Building cell therapies with pharmacologic operating systems to provide treating physicians with precise and dynamic control of engineered cells in patients.
  • enGene

    enGene has developed a robust non-viral gene-therapy platform to transport DNA sequences across mucosal barriers.
  • Freenome

    Making cancer screening and diagnostics as accurate and accessible as possible, through a fusion of machine learning, biology and computer science.
  • MiNA Therapeutics

    Harnessing the innate mechanism of gene activation, MiNA Therapeutics' platform enables the development of new medicines that restore normal function to patients’' cells.
  • Antheia

    Providing a stable and cost-competitive supply of plant-based medicines and to transform the discovery, manufacture, and distribution of medicines.
  • Atreca

    Atreca focuses on the immune responses of patients to discover and develop novel immunotherapies.
  • Neucyte

    NeuCyte is an innovative biotechnology company focused on CNS drug discovery. NeuCyte has developed an in vitro platform for neurotoxicity assessment, disease modeling, and more.
  • Samplix

    Samplix is a biotechnology company that has developed a proprietary technology for single molecule sample preparation.
  • Aether

    Aether Biomachines is repurposing enzymes to reinvent previously discovered compounds and create novel compounds.
  • Recursion Pharmaceuticals

    Discovering transformative new treatments by leveraging the speed of automation with the intelligence of computers.
  • Harpoon Therapeutics

    Leveraging a platform focused on T cell engagement to discover and develop novel biologics for the treatment of cancer and other diseases
  • Maverick Therapeutics

    Redirected T cell therapeutics designed to deliver potent activity with increased tumor specificity and reduced toxicity.
  • Distributed Bio

    Applying a computational immunology platform for mining of antibodies, TCRs and peptides. Global leaders in advanced antibody library analysis and design.
  • Scenic Biotech

    Scenic is pioneering genetic modifies for drug discovery to build a pipeline of breakthrough products.
  • Carisma Therapeutics

    Carisma Therapeutics is pioneering CAR macrophage immunotherapy to target solid tumors.
  • LogicBio Therapeutics

    Harnessing the body's natural DNA repair process to provide precise, stable, and durable therapies to patients with serious genetic diseases.
  • Finch

    Developing and delivering innovative therapies that harness the human gut microbiome.
  • Inari

    Developing and delivering innovative therapies that harness the human gut microbiome.
  • AgBiome

    AgBiome develops innovative, cutting-edge solutions using new knowledge of the plant-associated microbiome to create novel products.
  • Cue Biopharma

    Cue Biopharma is an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system.
  • Lumen Bioscience

    Lumen Bioscience makes oral antibody therapeutics.
  • EnginZyme

    EnginZyme engineers cost-competitive biocatalytic solutions fast than ever before, using their universal system for enzyme immobilization.
  • Insitro

    insitro will integrate cutting-edge machine learning techniques with the innovations that have occurred in life sciences that enable the creation of the large, high-quality data sets.
  • Hibercell

    HiberCell is developing first-in-class therapeutics that target dormant disseminated tumor cells from solid and liquid cancers to the prevent or delay the recurrence of cancer.
  • Rarecyte

    RareCyte is enabling next-generation analysis of rare cells with an open and end-to-end platform that supports clinical trials worldwide.
  • TScan Therapeutics

    TScan is harnessing novel T cell systems to extend the promise of immunotherapy.
  • Kymera Therapeutics

    Kymera Therapeutics is pioneering a new therapeutic modality and platform with the potential to transform drug discovery and deliver breakthrough medicines for previously untreatable diseases.
  • GeneQuine

    GeneQuine Biotherapeutics GmbH develops novel therapies for osteoarthritis, a degenerative joint disease with high unmet medical need.
  • Cedilla Therapeutics

    Cedilla is harnessing intrinsic protein stability mechanisms to broaden the reach of small molecule therapeutics to work on diseases caused by protein dysregulation.
  • Admirx

    Admirx is a preclinical-stage company developing anti-complement therapies to treat life threatening auto-immune and inflammatory diseases.
  • Cygnal Therapeutics

    Cygnal Therapeutics is developing drugs to manipulate exoneural biology for the treatment of cancer, immunological diseases, and regenerative processes.
  • Quentis Therapeutics

    Quentis Therapeutics is translating novel biology into new therapeutic approaches to address endoplasmic reticulum stress in multiple diseases.
  • Seer Bio

    Seer is a life sciences and health data company focused on capturing and translating deep molecular insights from the proteome to enable early detection of cancer and neurological diseases.
  • Invaio Sciences

    Invaio Sciences is a transformative early-stage startup developing a platform to control the fitness and behavior of pests and target insects in a targeted, sustainable, and natural way.
  • enEvolv

    Engineering microorganisms to produce valuable bio-based products from renewable feedstocks.
  • Orum

    Developing next-generation therapeutic antibodies to directly target cytosolic proteins associated with many human diseases that have been previously considered untreatable.
  • eGenesis

    Making xenotransplantation a routine medical procedure for the delivery of safe & effective human transplantable cells, tissues & organs.
  • Verseau

    Transforming immunotherapy.
  • Hexagon Bio

    Mining massive amounts of genomic data from fungal genomes to identify novel drugs for diseases with unmet needs.
  • Pandion Therapeutics

    Shifting the paradigm from systemic immunosuppression to localized immunomodulation with the next generation of targeted therapeutics.
  • Eligo Bioscience

    Developing a new class of targeted biotherapeutic agents to selectively intervene on the microbiome.
  • Senti Biosciences

    Leveraging expertise in cell engineering and biological programming to build the future of gene and cell based therapies.
  • Ribometrics

    Discovering small molecule drugs that target functional 3D RNA structures to treat human diseases.

Join over 170,000 scientists using
Benchling to power life science R&D